AMRN
Amarin Corporation plcNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
13.26
P/S
1.65
EV/EBITDA
-10.94
DCF Value
$0.33
FCF Yield
2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
65.7%
Operating Margin
-12.7%
Net Margin
-21.1%
ROE
-8.4%
ROA
-5.8%
ROIC
-4.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $19.4M | $-1.2M | $-0.00 |
| FY 2025 | $182.8M | $-38.8M | $-0.09 |
| Q3 2025 | $49.7M | $-7.7M | $-0.37 |
| Q2 2025 | $72.7M | $-14.1M | $-0.68 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IE
Exchange
NASDAQ
Beta
0.82
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.